This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
by Kinjel Shah
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.
REGNNegative Net Change SNYNegative Net Change AZNNegative Net Change LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
Pacira's Exparel Receives Permanent New Product-Specific J-Code
by Zacks Equity Research
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
PCRXPositive Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
by Zacks Equity Research
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
ANIPPositive Net Change RAREPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
by Zacks Equity Research
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
AZNNegative Net Change LLYPositive Net Change BAYRYNegative Net Change ABBVNegative Net Change
pharmaceuticals
Stock Market News for Oct 4, 2024
by Zacks Equity Research
U.S. stock markets closed lower on Thursday after a choppy session.
MRKNegative Net Change
pharmaceuticals
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
by Zacks Equity Research
Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.
SNYNegative Net Change AZNNegative Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
by Zacks Equity Research
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
GILDPositive Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
AZNNegative Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
pharmaceuticals
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
by Zacks Equity Research
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data.
VKTXPositive Net Change MDGLPositive Net Change AKROPositive Net Change SGMTNegative Net Change
pharmaceuticals
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
by Zacks Equity Research
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
SNYNegative Net Change AZNNegative Net Change LLYPositive Net Change JAZZPositive Net Change
pharmaceuticals
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
by Zacks Equity Research
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
BMYNegative Net Change ANIPPositive Net Change FULCPositive Net Change STTKNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNNegative Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: Coca-Cola, Pfizer and Altria
by Zacks Equity Research
Coca-Cola, Pfizer and Altria have been highlighted in this Investment Ideas article.
KONegative Net Change PFEPositive Net Change MOPositive Net Change
pharmaceuticals
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
NVOPositive Net Change LLYPositive Net Change ABBVNegative Net Change GMABPositive Net Change
pharmaceuticals
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
by Zacks Equity Research
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
BMYNegative Net Change PRMEPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology cell-therapy medical pharmaceuticals
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
AZNNegative Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
pharmaceuticals
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
PFEPositive Net Change MRNANegative Net Change ARCTNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
NVSPositive Net Change RHHBYNegative Net Change NVOPositive Net Change LLYPositive Net Change
medical pharmaceuticals
Zacks.com featured highlights include GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer
by Zacks Equity Research
GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer are part of the Zacks Screen of the Week article.
PFEPositive Net Change SONPositive Net Change PAMPositive Net Change GIIIPositive Net Change HGPositive Net Change
consumer-discretionary industrial-products insurance pharmaceuticals utilities
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
by Zacks Equity Research
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
REGNNegative Net Change SNYNegative Net Change PFEPositive Net Change LLYPositive Net Change
pharmaceuticals
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
by Zacks Equity Research
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
PFEPositive Net Change LLYPositive Net Change BAYRYNegative Net Change
medical pharmaceuticals
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
by Zacks Equity Research
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.
ABBVNegative Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
pharmaceuticals
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
ANIPPositive Net Change KRYSPositive Net Change SAVAPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
AZNNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYPositive Net Change
pharmaceuticals
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
by Zacks Equity Research
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
ABBVNegative Net Change ADMAPositive Net Change KRYSPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals